KHKiyohiko Hotta

Kiyohiko Hotta

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kiyohiko Hotta has a total of 232 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Clinical Utility of Virtual Crossmatch Reliability in Living Donor Kidney Transplantation

    by Naoya Iwahara, Kiyohiko Hotta, Takayuki Hirose, Makoto Ito, Hiroki Hashiguchi, Takashige Abe

    Donor‐specific antibodies (DSA) are associated with antibody‐mediated rejection (AMR) and graft loss in kidney transplantation. In deceased donor kidney transplantation, virtual crossmatch (VXM) using solid‐phase assays has largely replaced physical crossmatch (PXM). However, comparative data in living donor kidney transplantation (LDKT), particularly for Japanese recipients, remain limited. This study examined the correlation between VXM and PXM and evaluated the incidence of early AMR in Japanese LDKT. We retrospectively analysed 102 LDKT recipients between July 2012 and August 2020, all of whom underwent both VXM and PXM. Patients were stratified into four groups: VXM+/PXM+, VXM+/PXM−, VXM−/PXM+, and VXM−/PXM−. Discordant results were observed in 7% of cases. VXM+/PXM− cases involved low‐titre DSA undetectable by flow cytometric crossmatch (FCXM), whereas all VXM−/PXM+ cases were B‐cell FCXM‐positive in ABO‐incompatible recipients. In ABO‐compatible transplantation, AMR developed in 43% (3/7) of VXM+/PXM+ recipients, 0% (0/1) of VXM+/PXM−, and 2% (1/57) of VXM−/PXM− recipients; no VXM−/PXM+ cases were observed. The VXM+/PXM+ group demonstrated frequent severe AMR, with two cases progressing to chronic active AMR. In contrast, AMR in the VXM−/PXM− group was rare, mild, and successfully managed with steroid pulse therapy alone. These findings indicate that VXM provides reliable immunologic risk stratification in Japanese LDKT and can serve as a practical alternative to PXM without compromising clinical outcomes.

  • Short Pretransplant Dialysis Periods are Clinically Acceptable Without Compromising Kidney Transplant Outcomes: A Japanese Multicenter Study

    by Keisuke Maeda, Takayuki Hirose, Kiyohiko Hotta, Keita Takahashi, Naoya Iwahara, Keita Kawashiro, Shigeru Harada, Yusuke Takada, Haruka Higuchi, Hajime Sasaki, et al.

    Objectives: Preemptive kidney transplantation (PEKT) is known to have better outcomes than kidney transplantation (KT) after dialysis therapy. However, the effect of pretransplant dialysis duration (PTDD) on KT outcomes under good hemodialysis control remains unclear. We investigated the association between PTDD and KT outcomes in a Japanese cohort with favorable dialysis management. Methods: Among three institutions, 805 patients who underwent a living donor KT between 2001 and 2021 were enrolled in this study. Those who underwent more than one KT, multiple organ transplantations in addition to KT, or transplantations at < 20 years of age were excluded. Calcineurin inhibitors, mycophenolate mofetil, and steroids were the primary maintenance immunosuppressors. Results: The allograft survival rates of the non‐PEKT group were significantly lower than those of the PEKT group (hazard ratio [HR] 1.67, 95% confidence interval [CI] 1.04–2.70). Univariate analysis showed that ≥ 2 years of PTDD demonstrated the highest HR for allograft loss when PTDD was separated by year (95% CI 1.11–2.55). Multivariate analysis showed that ≥ 2 years of PTDD (HR 2.61 [95% CI 1.58–4.38]), being a male recipient (HR 2.35 [95% CI 1.30–4.53]), and having diabetic nephropathy (HR 2.94 [95% CI 1.71–4.98]) were suggested to be risk factors for allograft loss. Additionally, < 2 years of PTDD resulted in significantly higher allograft survival rates; the 10‐year allograft survival rates of recipients with ≥ 2 years and < 2 years of PTDD were 82.0% and 91.8%, respectively. Conclusions: Allograft survival remained unaffected when KT is performed after a short‐term dialysis introduction.

  • Clinicopathological Analysis of Immunologically High-Risk Kidney Transplantation Using High-Dose Intravenous Immunoglobulin as Desensitization Therapy

    by Tatsu Tanabe, Hajime Sasaki, Yutaka Shiono, Toyoshi Seito, Kazuhiro Ujihashi, Yusuke Takada, Haruka Higuchi, Daiji Takamoto, Keita Minami, Hiroshi Tanaka, et al.

    Introduction: High-dose intravenous immunoglobulin (H-IVIg) has been used as a desensitization therapy for donor-specific anti-HLA antibody (DSA)-positive kidney transplant recipients in Japan since 2019. This study reports the clinical and pathological outcomes of patients who received H-IVIg at Sapporo City General Hospital. Methods: This study included 7 patients who underwent kidney transplantation at our hospital and received H-IVIg as pretransplant desensitization therapy. At our institution, H-IVIg is indicated for patients with a history of sensitization, such as prior blood transfusion, pregnancy, or organ transplantation, and who tested positive in a flow cytometry crossmatch (FCXM) before transplantation. The recipients (mean age: 55.2 ± 11 years) included one male and six females. The donors (mean age: 62.8 ± 8.8 years) included five males and two females. All were living donor transplants, with four cases involving spousal donation. We assessed the immunological status before and after desensitization and retrospectively analyzed kidney function, anti-donor antibody status, and pathological findings. Results: Before desensitization, 6 patients were FCXM-T positive, and all were FCXM-B positive. After desensitization, 3 patients converted to FCXM-T negative; however, all remained FCXM-B positive. The Luminex single antigen test was positive in 4 patients before desensitization; one converted to negative, while one initially negative patient became positive. Consequently, 4 patients remained DSA positive at transplantation. Three patients experienced acute rejection within 1 month: one had antibody-mediated rejection (ABMR), and two had T-cell-mediated rejection. All patients responded to antirejection therapy, preserving their graft function. At 36 months of follow-up, all the patients survived with functional grafts. Pathological findings revealed early rejection in 3 patients, who later developed chronic ABMR. The remaining 4 patients did not experience rejection episodes. Conclusion: The H-IVIg regimen facilitates kidney transplantation in immunologically high-risk recipients. However, the risk of early postoperative rejection and the potential development of chronic ABMR necessitate careful posttransplant monitoring.


  • Open Access

    Potential of Kidney Exchange Programs (KEPs) in Japan for Donor-Specific Antibody-Positive Kidney Transplants: A Questionnaire Survey on KEPs and a Multi-Institutional Study Conducting Virtual Cross-Matching Simulations

    by Taihei Ito, Miki Ito, Naohiro Aida, Kei Kurihara, Akihiro Terao, Yoshihiko Watarai, Mitsuru Saito, Keizo Kaku, Daisuke Ishii, Satoshi Sekiguchi, et al.

    Objectives: To clarify the need for a kidney exchange program (KEP) in Japan by conducting a questionnaire survey on KEPs and simulated KEPs by virtual cross-matching based on past cases of transplantation avoidance. Methods: In addition to the content regarding KEPs, an electronic survey was conducted to investigate the number of cases of kidney transplant abandonment due to “immunological” reasons over the past 10 years (2012–2021). Virtual cross-matching was conducted to simulate the feasibility of avoiding immunological risks and enabling kidney transplantation in patients who were previously unable to undergo the procedure. Results: The survey received responses from 107 facilities (response rate: 81.7%). In response to the question about the necessity of a KEP in Japan, 71 facilities (66.4%) indicated that KEPs are necessary. In addition, 251 living-donor kidney transplants were abandoned for “immunological” reasons over the past decade (2012–2021). Among the 80 pairs for which detailed information was available, virtual cross-matching simulations showed that 37/80 pairs (46.3%) were donor-specific antibody (DSA)-negative for blood type-matched combinations, and 41/80 pairs (51.3%) were DSA-negative for blood type-incompatible transplants. Conclusions: The need for a KEP in Japan and its potential usefulness were demonstrated.


  • Clinical Trials for Developing Treatment and Early Diagnostic Methods for Chronic Active Antibody-Mediated Rejection in Kidney Transplantation: A Review

    by Kiyohiko Hotta

    Background: Development of immunosuppressants has reduced the incidence of acute T-cell-mediated rejection (TCMR) and significantly improved the short-term outcome of kidney transplantation. However, in the long term, many cases of transplanted kidney failure are due to chronic active antibody-mediated rejection (CAAMR) caused by donor-specific antibodies. Overcoming this is essential for improving long-term outcomes. The mechanism of CAAMR remains largely unknown and no effective treatment is currently available. Summary: Various therapeutic approaches have been attempted for cases that have progressed to CAAMR. However, an effective treatment method has yet to be established. Therefore, efforts are underway to develop diagnostic methods for identifying patients at risk of developing CAAMR either before its occurrence or as early as possible. Recent reports have identified potential biomarkers in the urine and blood for the early diagnosis of CAAMR. In addition, the molecular analyses of kidney allograft biopsy tissues are being explored for early diagnostic methods. This review summarizes the current treatments for CAAMR and the trials aimed at developing early-stage diagnostic methods for detecting CAAMR. Key Messages: Various new diagnostic methods have successively attempted to replace histological examination in the diagnosis of kidney transplant rejection; most have focused on TCMR or acute antibody-mediated rejection. The development of early diagnostic methods for CAAMR is still in its infancy and future advancements are anticipated.


  • Current Progress in Kidney Xenotransplantation: Time to Proceed to Clinical Trials

    by Takayuki Hirose, Kiyohiko Hotta, Tatsuo Kawai

    Kidney transplantation is the ideal treatment for end‐stage kidney disease, but the shortage of donors limits its clinical implementation. Although xenotransplantation, particularly from pigs, is a promising approach to address the donor shortage, significant challenges, such as immune rejection and disease transmission, exist. However, recent advances in gene‐editing technology as well as development of novel immunosuppressive drugs have significantly improved xenotransplant outcomes in nonhuman primates. Recent studies on xenotransplantation using decedent recipients have provided novel insights into human immune responses to porcine xenografts, despite the limited observation time in these recipients. Building upon these preclinical studies, four cases of clinical kidney xenotransplantation have recently been performed under a “expanded access authorization.” Understanding immunological responses, as well as various physiological discrepancies between human and porcine kidney function, must be enhanced before xenotransplantation can become a viable clinical solution to organ shortages. This review summarizes the current progress of kidney xenotransplantation in nonhuman primate models, decedent models, and clinical cases.


  • Enhanced SARS-CoV-2 BA.2.86 Neutralization After BA.5 Infection in Vaccinated Kidney Transplant Recipients

    by Keita Kawashiro, Kiyohiko Hotta, Rigel Suzuki, Naoya Iwahara, Takayuki Hirose, Shuhei Tsujino, Takasuke Fukuhara, Nobuo Shinohara

  • Successful kidney transplantation improves atrophic bladder capacity and function within 3 months in long‐term dialysis patients

    by Tatsuya Hoshi, Takayuki Hirose, Kanako Fuyama, Naoya Iwahara, Hiroki Chiba, Kiyohiko Hotta


  • Protocol biopsy of kidney allograft enables early detection of BK virus nephropathy to preserve kidney allograft function

    by Naoya Iwahara, Kiyohiko Hotta, Takayuki Hirose, Hiromi Okada, Nobuo Shinohara

    Background: The Banff Working Group has updated the histological classification of BK virus nephropathy (BKVN), highlighting the importance of early detection. However, an early detection strategy for BKVN using biopsy has not yet been established. Our investigation aimed to assess the efficacy of protocol biopsy for the diagnosis of BKVN. Methods: We performed a retrospective cohort study of 314 patients who had undergone kidney transplantation between 2006 and 2021. Kidney allograft biopsies were performed as part of a protocol biopsy at 3 months and 1 year post‐transplantation. Following the diagnosis of BKVN, the immunosuppressant dose was reduced. Results: Twelve patients (3.8%) were diagnosed with BKVN by biopsy. Most diagnoses are established during the early stages of BKVN (polyomavirus nephropathy class 1 in six, class 2 in five, and class 3 in one). Following the reduction in immunosuppressant dose, kidney allograft function did not deteriorate in any patients. Additionally, test for BK virus DNA in the blood was negative. All but one patient demonstrated histological resolution of BKVN, and the other had a very slight positivity for the simian virus 40 large T antigen. The median follow‐up time after BKVN diagnosis was 6 years. One patient developed de novo donor‐specific antibody and subclinical acute antibody‐mediated rejection that was successfully cured. Conclusions: Our analysis indicates that protocol biopsy may enable the early detection of BKVN, resulting in the preservation of kidney function. image